clinical trial · NCT06864793
Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers
Qilu Pharmaceutical Co., Ltd.·phase1·active not recruiting·n = 48
Infertility, FemaleQL1012DGonal-F®
brief summary
The goal of this Interventional study is to Compare the Pharmacokinetics and Safety of Recombinant Human Follicle Stimulating Hormone Injection (QL1012D) and Gonal-F® in Healthy Female Volunteers. It aims to evaluate the bioequivalence of recombinant human follicle stimulating hormone injection (QL1012D) and Gonal-F®, both given subcutaneously.
started
Apr 6, 2025
primary completion
Feb 4, 2026
completion
Apr 1, 2026
last updated
Feb 17, 2026
official title
A Randomized, Double-blind, Two-Period, Crossover Study to Compare the Pharmacokinetics and Safety of Recombinant Human Follicle Stimulating Hormone Injection (QL1012D) and Gonal-F® in Healthy Female Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol